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Abstract 21 
Brain-eating amoebae (Acanthamoeba spp., Balamuthia mandrillaris and Naegleria 22 
fowleri) can cause opportunistic infections involving the central nervous system. It is 23 
troubling that the mortality rate is more than 90% despite advances in antimicrobial 24 
chemotherapy over the last few decades. Here, we describe urgent key priorities for 25 
improving outcomes from infections due to brain-eating amoebae. 26 
Dear Editor 27 
Whilst brain infections due to pathogenic free-living amoebae are rare, the mortality 28 
remains very high leading almost always to death.1-4 Defining the global burden of infections 29 
due to brain-eating amoebae presents a major challenge, as infections are rare but insidious in 30 
nature leading to inherent difficulty in their diagnosis due to a global lack of capacity for 31 
diagnostics especially in developing countries. Lack of effective drugs and/or their delivery 32 
to the site of infection results in mortality rate of more than 95%, highlighting global failure 33 
in tackling this infection over the past several decades. Despite exceptionally high mortality 34 
rate, brain-eating amoebae have not had the expected level of focus from the global 35 
community. There is a need for renewed efforts for:  36 
(i) Better epidemiology date involving collaborative efforts between basic 37 
scientists and clinical researchers to accelerate translational medicine.  38 
(ii) Improved laboratory and point-of-care testing. It is obvious that, without 39 
point-of-care testing, these infections will remain difficult to diagnose, and 40 
treat, and their true global burden will remain undetermined. 41 
(iii) Better access to drugs. Access to established medicines, as well as 42 
development of new medicines. Access, in particular to Miltefosine is 43 
particularly, and liposomal amphotericin B (Ambisome) remains very 44 
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expensive in many countries. Acceleration of vaccination programmes should 45 
be a key priority, but will be challenging due to the rarity of the disease.   46 
(iv) Capacity building for pathogenic free-living amoebae. Whilst there are several 47 
groups working in the area of brain-eating amoebae, better cohesion and 48 
extension within basic scientists and practicing physicians will enable more 49 
rapid progress in this area.  50 
(v) Funding for development of diagnosis, treatment strategies, and 51 
implementation programmes, especially in resource-limited settings. In this 52 
regard, establishment of advocacy groups and public engagement will lead to 53 
infrastructure development programme for disease surveillance and to devise 54 
treatment strategies.  55 
(vi) Fundamental research in genomics-based studies of amoebal evolution, 56 
parasite-host interactions, and resistance in the host including metabolic 57 
adaptation and understanding the innate and acquired immune responses 58 
remain priority areas.  59 
Although there are some encouraging novel therapies on the horizon including intranasal 60 
delivery of antiamoebic molecules to bypass blood-brain barrier selectivity,5 there is an 61 
urgent need in delivering novel diagnostic and therapeutic strategies to limit mortality from 62 
these infections. However, engagement of major funding bodies and governmental and non-63 
governmental agencies is needed to enable substantial reductions in the unacceptably high 64 
mortality from infections due to brain-eating amoebae.  65 
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